New Horizon Health Limited ( (HK:6606) ) just unveiled an announcement.
New Horizon Health Limited has announced a delay in the publication of its 2024 annual results and report, as well as the postponement of its annual general meeting, while trading in its shares remains suspended. Despite these challenges, the company continues its business operations and is actively working on resumption progress, keeping shareholders and potential investors informed about its financial position and operational developments.
More about New Horizon Health Limited
New Horizon Health Limited is a commercial stage biotech company focused on developing and commercializing innovative cancer screening products to meet significant unmet medical needs in the cancer screening industry in China.
Technical Sentiment Signal: Hold
Current Market Cap: HK$6.47B
For detailed information about 6606 stock, go to TipRanks’ Stock Analysis page.